Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 3/20 | 0.39 |
| ▸ | MMP12 | P39900 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP14 | P50281 | 3/20 | 0.39 |
| ▸ | MMP16 | P51512 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045799 | 0.83 | MTNR1A (0.43) | TRPV1MBOAT4RXRATUBB4ATUBB | |
| SCHEMBL13136015 | 0.82 | MBOAT4 (0.46) | TRPV1MBOAT4TUBB4ATUBBTUBA3C | |
| SCHEMBL31045873 | 0.82 | TRPV1 (0.45) | TRPV1MBOAT4PTGS1 | |
| SCHEMBL17986246 | 0.81 | MBOAT4 (0.45) | TRPV1MBOAT4HSD17B10TUBB4ATUBB | |
| SCHEMBL13757105 | 0.81 | MBOAT4 (0.45) | TRPV1MBOAT4HSD17B10TUBB4ATUBB | |
| SCHEMBL3558234 | 0.80 | MBOAT4 (0.49) | TRPV1MBOAT4RXRARXRBRXRG | |
| SCHEMBL23287266 | 0.78 | MBOAT4 (0.45) | TRPV1MBOAT4HSD17B10TUBB4ATUBB | |
| SCHEMBL2528780 | 0.78 | MBOAT4 (0.48) | TRPV1MBOAT4HSD17B10PDE4B | |
| SCHEMBL4472362 | 0.78 | MBOAT4 (0.45) | TRPV1MBOAT4HSD17B10TUBB4ATUBB | |
| SCHEMBL3541953 | 0.76 | POLB (0.60) | HSD17B10TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858639-B2 | [1,2,4]triazolo[4,3-a]pyridazine derivatives such as 6-(2-chlorophenyl)-7-(4-chlorophenyl)-3-[[2-methyl-6-(trifluoromethyl)pyridin-3-yl]methyl]-[1,2,4]triazolo[4,3-a]pyridine, used for the treatment of obesity and hyperlipemia, or as antidiabetic, antilipemic, anticholesterol and hypotensive agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287324-A1 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | CNR1, CNR2, GPR18 | TRPV1 61/4885MBOAT4 1904/4885RXRA 262/4885 |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TRPV1 61/4885MBOAT4 1904/4885RXRA 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.